Waqf Bill passed in Lok Sabha: A complete guide to controversy, amendments, and NDA vs INDIA showdown
Bill, 2025, in the Lok Sabha ignites a fierce debate over property management and rights for Muslim communities in India.
Legal Futures11h
Settlement agreement legal fees part of NDA problem, MPs told
The money employers have to pay employees for legal advice on settlement agreements is not enough to deal with the NDAs they ...
Employers must be stopped from using non-disclosure agreements, says ex-minister
Labour former minister Louise Haigh argued that employers cannot be trusted with this ‘tool of oppression’. A Labour former ...
Waqf Bill to be tabled in Lok Sabha today: What’s a whip? What’s the role? Explained in 5 points
The BJP and the Congress have issued a crucial whip for its MPs to ensure attendance for the Waqf (Amendment) Bill discussion ...
Oneindia1d
Waqf Amendment Bill: Will Nitish Kumar And Chandrababu Naidu Back The Bill In Parliament? Know The Number Game
The Waqf Amendment Bill has turned out to be a litmus test for BJP-led National Democratic Alliance (NDA) as it has to prove the majority in the Lok Sabha. The government is already facing strong ...
Parliament Braces For NDA And INDI Bloc Face-Off As Waqf Bill Goes To Lok Sabha Floor Today
Lok Sabha members will speak on the bill for eight hours– 4.40 hours for the ruling National Democratic Alliance (NDA) and ...
Former Faith Life Church employees allege nondisclosure agreements meant to silence them
A nondisclosure agreement The Dispatch reviewed says it's "a precondition to … continual employment." Those who didn't sign say they risked dismissal.
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...
TMCnet5d
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...